The mandate to realize surrogate endpoints in the context of human clinical trials with conditionally replicative adenovirus (CRAd) agents has thus suggested the utility of imaging analysis. In theory, this type of assay could provide critical information with respect to CRAd replication, amplification, and localization. These types of studies could thereby provide key insight into CRAd function in a human clinical context. To address this key issue we have developed a novel labeling system based upon structural incorporation of imaging reporter motifs into the adenovirus capsid. We hypothesize that this approach will provide the basis of deriving useful surrogate endpoint read-outs allowing valid imaging analysis of a human CRAd intervention for carcinoma of the ovary. In this regard, we have recently demonstrated our ability to incorporate complex heterologous fusion proteins at adenovirus minor capsid sites. Proof-of-principle studies with direct incorporation of fluorescent or SPECT/PET-linked imaging motifs validated that functional reporters could be incorporated within the adenovirus capsid and provide imaging signal. These demonstrated capacities provide the framework for understanding if such imaging detection systems can be employed in combination via capsid incorporation of dual modality reporter fusions which embody the capacity for SPECT/PET and fluorescent monitoring. Furthermore, the validation of this approach in relevant animal model systems will provide the rationale for clinical translation of this strategy as a means to derive useful surrogate endpoints of CRAd function in the context of human clinical employ. On the basis of these considerations, the Specific Aims of our proposal are:
Specific Aim #1 : To develop candidate ovarian cancer CRAd agents which embody capsid incorporated dual modality structural reporter fusions allowing dynamic fluorographic and SPECT/PET-based imaging analysis.
Specific Aim #2 : To employ the derived dual imaging modality CRAds in orthotopic murine models of carcinoma of the ovary to validate SPECT/PET and fluorographic imaging analysis of CRAd functionally.
Specific Aim #3 : To employ the optimal imaging modality for CRAd-based imaging analysis in the context of our next generation CRAd agent to be employed in a Phase I human clinical trial for carcinoma of the ovary to validate the analytical value of the structural reporter fusion method for CRAd monitoring. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA121187-02
Application #
7463840
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Tandon, Pushpa
Project Start
2007-07-05
Project End
2012-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
2
Fiscal Year
2008
Total Cost
$275,500
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Ugai, Hideyo; Dobbins, George C; Wang, Minghui et al. (2012) Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1. Virology 432:283-95
Kim, Kenneth H; Dmitriev, Igor; O'Malley, Janis P et al. (2012) A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18:3440-51
Gamble, Lena J; Ugai, Hideyo; Wang, Minghui et al. (2012) Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, ?24DoubleRGD, in an ovarian cancer model. J Mol Biochem 1:26-39
Kim, Kenneth H; Ryan, Michael J; Estep, James E et al. (2011) A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-?24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther 22:821-8
Mathis, J Michael; Bhatia, Shilpa; Khandelwal, Alok et al. (2011) Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. PLoS One 6:e16792
Rein, Daniel T; Volkmer, Anne; Beyer, Ines M et al. (2011) Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol Oncol 123:138-46
Yamamoto, Masato; Curiel, David T (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18:243-50
Paupoo, A A V; Zhu, Z B; Wang, M et al. (2010) A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. Hum Reprod 25:2068-83
Kimball, Kristopher J; Preuss, Meredith A; Barnes, Mack N et al. (2010) A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 16:5277-87
Borovjagin, Anton V; McNally, Lacey R; Wang, Minghui et al. (2010) Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging 9:59-75

Showing the most recent 10 out of 14 publications